Related Experiment Video
Updated: May 20, 2026
08:27
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
Beyond dopamine: glutamate as a target for future antipsychotics
Kyra-Verena Sendt1, Giovanni Giaroli, Derek K Tracy
1Department of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF, UK.
ISRN Pharmacology
|July 26, 2012
Summary
Schizophrenia treatment shows limited success with dopamine-focused drugs. New research explores targeting glutamate pathways, offering hope for better therapies, especially for negative and cognitive symptoms.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- The dopamine hypothesis has long guided schizophrenia pharmacotherapy.
- Current antipsychotics targeting dopamine offer limited efficacy for many patients, leading to poor treatment response and adherence.
- Emerging evidence highlights the crucial role of glutamate system dysfunctions in schizophrenia pathophysiology.
Purpose of the Study:
- To review recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia.
- To discuss novel pharmacological targets within the glutamate system for schizophrenia treatment.
- To evaluate the potential of new compounds for improving schizophrenia pharmacotherapy.
Main Methods:
- Literature review of recent findings on neurotransmitter systems in schizophrenia.
- Analysis of evidence for glutamatergic and dopaminergic interactions in schizophrenia.
- Overview of novel antipsychotic compounds targeting the glutamate synapse.
Main Results:
- Glutamate pathways are increasingly recognized as critical in schizophrenia.
- Novel drug candidates targeting NMDA receptors and metabotropic glutamate receptors (mGluRs) show promise.
- Compounds modulating glutamatergic neurotransmission may offer new treatment avenues.
Conclusions:
- The glutamate system presents a promising target for novel antipsychotic drug development.
- Targeting glutamate, particularly for negative and cognitive symptoms, is a key area for future research.
- Integrating glutamatergic and dopaminergic strategies may lead to more effective schizophrenia treatments.
Related Concept Videos
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...